{"entity":{"id":"nct07631013","kind":"trial","name":"Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions","aka":[],"tldr":"This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.","summary":"The registry lists NCT07631013 as not yet recruiting, last updated 2026-06-11. Enrolment is 36 planned participants, an estimate. Interventions: TROP2 CAR/IL-15 TGFBR2 KO NK cells. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.","status":"planned","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07631013","url":"https://clinicaltrials.gov/study/NCT07631013"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07631013","phase":"1","setting":"Phase 1 Dose Escalation And Expansion Study Of Intralesional TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions","sponsor":"M.D. Anderson Cancer Center","started":"2026-12-31","startedType":"estimated","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07631013/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}]}}